帕博西尼联合来曲唑与多西他赛联合表柔比星一线治疗晚期乳腺癌的循证药物经济学评价

{"title":"帕博西尼联合来曲唑与多西他赛联合表柔比星一线治疗晚期乳腺癌的循证药物经济学评价","authors":"","doi":"10.5246/jcps.2023.03.019","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":15329,"journal":{"name":"Journal of Chinese Pharmaceutical Sciences","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Evidence-based pharmacoeconomic evaluation of palbociclib in combination with letrozole versus docetaxel in combination with epirubicin in the first-line treatment of advanced breast cancer with epirubicin\",\"authors\":\"\",\"doi\":\"10.5246/jcps.2023.03.019\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":15329,\"journal\":{\"name\":\"Journal of Chinese Pharmaceutical Sciences\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-03-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Chinese Pharmaceutical Sciences\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.5246/jcps.2023.03.019\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Chinese Pharmaceutical Sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5246/jcps.2023.03.019","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}